Case Report

A Case Study of a Patient with Diplopia and Bilateral Facial Palsy Due to Atypical Miller Fisher Syndrome: Treatment with Complex Korean Medicine

Chae Hyun Park, Jae Hui Kang, Hwa Yeon Ryu, Ga Hyeon Jung, Yong Ho Ku, Hyun Lee*

Department of Acupuncture and Moxibustion Medicine, College of Korean Medicine, Daejeon University, Cheonan, Korea

ABSTRACT

Miller Fisher syndrome (MFS) is a rare variant of Guillain–Barré syndrome characterized by ocular paralysis, ataxia, and insensitivity. This report describes the effect of Complex Korean Medicine Treatment (CKMT) on a patient previously diagnosed with MFS presenting with diplopia and facial palsy. The distance at which diplopia occurs, the diplopia questionnaire, the range of diplopia, the degree of facial paralysis, and the degree of ptosis were evaluated at the time of admission and weekly for 1 month. After receiving CKMT for 4 weeks the 62-year-old female had improved symptoms of diplopia, bilateral facial palsy and ptosis caused by MFS. These results show the significant association of MFS with facial paralysis and the improvement achieved with CKMT.

©2021 Korean Acupuncture & Moxibustion Medicine Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Miller Fisher syndrome (MFS), a type of acute inflammatory polyneuropathy, was first described by Collier as a variant of Guillain–Barré syndrome (GBS) in 1932 [1]. The initial diagnosis of GBS is based on clinical presentation e.g., with numbness, pins and needles, muscle weakness, pain, problems with balance and coordination. In addition, presence of GQ1b antibody, lumbar puncture, and cerebral spinal fluid analysis are used to diagnose GBS [2]. However, not every MFS patient shows GQ1b antibody positivity, and this variant is called atypical MFS [3].

The treatment for MFS includes administration of steroids, intravenous immunoglobulins (IVIG), and plasma exchange [4]. In a recent study, there was no clear conclusion about the effect of immunoglobulin treatment, however the study was small [5].

Evaluation of the treatment for MFS entails an assessment of eye movement, the distance at which diplopia occurs, and use of the diplopia questionnaire. This report describes the improvement in symptoms of diplopia and facial palsy after receiving complex Korean medical treatment (CKMT) at the Cheonan Korean Medicine Hospital of Daejeon University in a patient diagnosed with atypical MFS who had not shown improvement after IVIG and steroid treatment received previously at Dankook University Cheonan Hospital.

Case Report

Patient

OOO (F/62)

Chief complaint

Diplopia, bilateral facial palsy, sight problems, ptosis

Medical history

Hospitalization due to norovirus gastroenteritis in March 2020. On medication for osteoporosis since May 2020.
Family history
Mother has hypertension.

Present illness
During hospitalization due to syncope that occurred on May 12th, 2020, the patient complained of diplopia and underwent a brain MRI, which showed normal findings. Soon after, the patient complained of ptosis and bilateral facial palsy. Cerebral spinal fluid examination showed albuminocytological dissociation, and the blood test was anti-GQ1b Ab negative. Thus, she was diagnosed with atypical MFS at Dankook University Cheonan Hospital, on June 6th, 2020. She received IVIG 5 times during hospitalization at Cheonan Hospital but did not show any improvement. After steroid pulse therapy, the patient showed a slight improvement in diplopia and facial palsy.

The patient visited Cheonan Korean Medicine Hospital of Daejeon University. After hospitalization, steroid oral administration therapy was continued for 5 days.

Duration of treatment
The duration of treatment lasted from June 18th, 2020, to July 17th, 2020 (30 days of hospitalization).

To protect the patient’s personal information, medical records were obtained from the Institutional Review Board (no.: DJUMC-2020-BM-13).

Treatment
Acupuncture
The acupuncture needles used were 0.20 × 30 mm stainless steel standardized and disposable (Eastern acupuncture equipment manufacturer, Boryung, Korea). Acupuncture was administered twice daily for 15 minutes: bilateral BL2, Ex-HN4, TE23, GB1, BL1, Ex-HN7, ST4, ST6, TE17, LI4, ST36, and ST9. Electroacupuncture treatment was administered once daily for 15 min. The machine used for electroacupuncture was STN-110 (Stratek, Seoul, Korea), set with a stimulation frequency of 3 Hz (Table 1).

Pharmacopuncture
Pharmacopuncture was performed once daily on each day of hospitalization. The acupoints were TE17, ST6, and ST9. Hominis placenta pharmacopuncture (Korean Pharmacopuncture Institute, Seoul, Korea) was administered just before acupuncture therapy in the afternoon. Doses of 0.2 mL were inserted at each acupoint to a depth of 0.5-1.0 mm. The maximum total dose per treatment was 1.0 mL. This was administered using a 1.0 mL disposable syringe and needle (Jungrim Medical, Seoul, Korea, 30 G × 12.7 mm needle (Table 1).

Herbal medicine
The patient took herbal medication 3 times daily; Bojungikgitang-gamibang, Soyo-san, Samulgwibitang, and Kikukjihwangtang were given (Table 2).

Physiotherapy
Silver spike point and manual therapy were administered on the mimic muscles once daily.

Moxibustion treatment
Indirect electric moxibustion (Technoscience, Seoul, Korea) therapy was applied once daily at LI4 and ST36.

Table 1. Treatment Intervention.

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Detail</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acupuncture rationale</td>
<td>Reasoning</td>
<td>Textbook of Acupuncture and Moxibustion Medicine</td>
</tr>
<tr>
<td></td>
<td>Variation</td>
<td>Almost same</td>
</tr>
<tr>
<td>Needling details</td>
<td>Points used</td>
<td>Bilateral BL2, Ex-HN4, TE23, GB1, BL1, Ex-HN7, ST4, ST6, TE17, LI4, ST36 and sternocleidomastoid</td>
</tr>
<tr>
<td></td>
<td>No. of needling</td>
<td>23 needles at 1 session</td>
</tr>
<tr>
<td></td>
<td>Depths of insertion</td>
<td>0.2-0.5 cm on acupoints</td>
</tr>
<tr>
<td></td>
<td>Response sought</td>
<td>Subjective De-qi sensation</td>
</tr>
<tr>
<td></td>
<td>Needle stimulation</td>
<td>Manual stimulation of rotation, lifting and thrusting</td>
</tr>
<tr>
<td></td>
<td>Needle retention time</td>
<td>15 min</td>
</tr>
<tr>
<td></td>
<td>Needle type</td>
<td>0.20 × 30 mm stainless steel standardized, and disposable</td>
</tr>
<tr>
<td>Treatment regimen</td>
<td>Number of sessions</td>
<td>60 sessions</td>
</tr>
<tr>
<td></td>
<td>Frequency/ duration</td>
<td>Twice a day for 30 d</td>
</tr>
<tr>
<td>Co-interventions</td>
<td>Other components of treatment</td>
<td>Electro-acupuncture, pharmacopuncture, herbal medicine, Moxibustion and physical therapy treatment.</td>
</tr>
<tr>
<td>Practitioner background</td>
<td>Duration of clinical experience</td>
<td>2 Korean medicine doctors.</td>
</tr>
<tr>
<td></td>
<td>1) Resident trainee in acupuncture and moxibustion medicine with 1 year of experience</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2) Specialist of acupuncture and moxibustion medicine with more than 25 years of experience</td>
<td></td>
</tr>
</tbody>
</table>
Evaluation

Diplopia questionnaire

In this case report the diplopia questionnaire was used to evaluate the severity of diplopia [6]. The questionnaire evaluation was conducted a total of 5 times, once a week, from June 18th, 2020, to July 16th, 2020 (Fig. 1; Appendix A).

The distance at which diplopia occurs

The distance at which the patient’s diplopia appeared was measured from the patient’s glabella and expressed in meters. This method is often used to evaluate diplopia [7]. The maximum length that could be measured in the hospital room was 30 m (Fig. 2).

\[
\begin{array}{|c|c|c|c|c|}
\hline
\text{Bojungikgitang-gamibang} & \text{Soyo-san} & \text{Samulgwibitang} & \text{Kikukjihwangtang} \\
\text{2020.06.18 - 2020.06.30} & \text{2020.07.01 - 2020.07.05} & \text{2020.07.06 - 2020.07.09} & \text{2020.07.10 - 2020.07.25} \\
\hline
\text{Atractylodis Rhizoma Alba} & 16 & Atractylodis Rhizoma Alba & 12 & \text{Castanches Herba} & 32 \\
\text{Paeoniae Radix Alba} & 12 & \text{Paeoniae Radix Alba} & 12 & \text{Angelicae Gigantis Radix} & 12 & \text{Rehmanniae Radix Preparat} & 20 \\
\text{Astragali Radix} & 12 & \text{Hoelen} & 8 & \text{Cnidii Rhizoma} & 12 & \text{Lycii Fructus} & 20 \\
\text{Crataegii Fructus} & 12 & \text{Bupleuri Radix} & 8 & \text{Paeoniae Radix Alba} & 12 & \text{Mori Fructus} & 20 \\
\text{Citri Péricarpium} & 12 & \text{Angelicae Gigantis Radix} & 8 & \text{Salviae Miltiorrhizae Radix} & 2 & \text{Corni Fructus} & 20 \\
\text{Raphani Semen} & 8 & \text{Liriopes Radix} & 8 & \text{Polygonae Radix} & 8 & \text{Gastrodiae Rhizoma} & 8 \\
\text{Poria cocos} & 8 & \text{Glycyrrhizae Radix} & 4 & \text{Atractylodis Rhizoma Alba} & 8 & \text{Chrysanthemi Flos} & 16 \\
\text{Ginseng Radix} & 8 & \text{Pinelliae Praeparatum} & 4 & \text{Hoelen cum Pini Radix} & 8 & \text{Phellodendri Cortex} & 16 \\
\text{Angelicae Gigantis Radix} & 8 & \text{Zingiberis Rhizoma} & 24 & \text{Coptidis Rhizoma} & 8 & \text{Alismatis Rhizoma} & 12 \\
\text{Platycodi Radix} & 6 & \text{Bambusae Caulis In Taeniam} & 8 & & & & \\
\text{Uncariae Ramulus} & 6 & \text{Crataegii Fructus} & 8 & & & & \\
\text{Perilla Herba} & 6 & \text{Amomi Fuctus} & 8 & & & & \\
\text{Osterici Radix} & 6 & \text{Lycii Fructus} & 8 & & & & \\
\text{Ledebouriella divaricata} & 6 & \text{Astragali Radix} & 8 & & & & \\
\text{Bombycis Corpus} & 6 & \text{Ginseng Radix} & 8 & & & & \\
\text{Angelicae dahurica} & 6 & \text{Zizyphi Spinosae Semen} & 8 & & & & \\
\text{Bupleuri Radix} & 4 & \text{Aucklandiae Radix} & 8 & & & & \\
\text{Cimicifugae Rhizoma} & 4 & \text{Acori Graminei Rhizoma} & 8 & & & & \\
\text{Pinelliae Praeparatum cum Zingiberis} & 4 & \text{Massa Medicata Fermentata} & 8 & & & & \\
\text{Aucklandiae Radix} & 4 & \text{Hordei Fructus Germinatus} & 8 & & & & \\
\text{Massa Medicata Fermentata} & 4 & \text{Galli Stomachichum Corium} & 8 & & & & \\
\text{Amomi Fuctus} & 4 & \text{Glycyrrhizae Radix} & 4 & & & & \\
\text{Glycyrrhizae Radix} & 4 & \text{Zingiberis Rhizoma} & 24 & & & & \\
\text{Jujubae Fructus} & 16 & & & & & & \\
\hline
\end{array}
\]

Fig. 1. Scores from the diplopia questionnaire over treatment time. The score decreased to 13 points on July 16th, 2020 from 25 points on June 18th, 2020, showing improvement in the diplopia the patient experienced.
Field of diplopia
To determine the degree of diplopia, the distance between the points was measured by marking the position where the center point was visible at a constant distance of 60 cm from the glabella of the patient. Since the patient complained of diplopia in all directions, this method was used to measure the degree and change in diplopia according to the direction (Fig. 3) [8].

Yanagihara system
To determine the degree of facial palsy, the Yanagihara scoring system [9] was used to measure 10 aspects of different facial function. The maximum score to grade the degree of nerve damage in facial nerve palsy is 30, and it was measured daily. (Fig. 4).

Photographs of ptosis
To evaluate the changes in ptosis, photos were taken once a week. Photographs of ptosis taken on July 16th, 2020, in the front view showed that the pupils were clearly more visible compared with photographs taken on June 18th, 2020 (Fig. 5).

Subjective state of the patient
The patient’s symptoms, such as dry eye syndrome, ocular fistula, and blurred vision were recorded electronically. Although subjective, these observations were used as indications of symptom improvement. On the day of admission, the patient complained that her eyes were easily tired and her vision was blurred. On Day 3, after admission, the patient said that her eyes were less watery and less tired. On Day 13, the patient reported that her eyes were not watering. On Day 38, dry eye syndrome had slightly improved. On September 4th, 2020, normal findings were reported in the dry eye test and keratography. Blurred vision with cataract was diagnosed at another hospital after discharge (Fig. 6).
Discussion

The male/female ratio of MFS is 2:1, with a mean age of 43.6 years at the onset of the disease [4]. The first symptoms of MFS are diplopia (38.6%) or ataxia (20.6%) [4]. In 57% of cases, the cranial nerves (other than the ocular motor nerve) such as the facial nerve (46%), glossary nerve and the vagus nerve (40%), and sublingual nerve (13%) may also be involved in MFS [4]. To diagnose MFS, the presence of a prior infection is reviewed, detection of anti-GQ1b antibodies, and cerebral spinal fluid analysis are used [2]. To treat MFS, steroid therapy, IVIG, or plasma exchange may be performed. However, more research is needed on their effects [5].

Acupuncture causes microscopic damage that increases local blood flow and promotes cell recovery [10]. You et al [11] treated ophthalmoplegia with acupuncture on acupoints GV20, BL2, Ex-HN4, TE23, ST2, TE17, LI04, LR03, and ST36. Wang et al [12] reported using TE12, GB1, Ex-HN4, ST4, ST6, ST7, GB20 acupoints for patients with MFS, facial paralysis and diplopia. In this current case, acupoints around the eyeball were selected (similar to other studies [8,11,12]) that facilitate the movement of eye muscles and affects the recovery of paralyzed muscles when stimulated with low-frequency electroacupuncture [13]. Although there are not many existing studies of MFS acupuncture treatment the most frequently used acupoints around the eyes were used to treat diplopia associated with MFS. In addition, since the patient also complained of facial paralysis acupoints used for facial paralysis were also used. Pharmacopuncture for facial nerve palsy may have the effect of supplementing qi and blood [14].

Bojungikgitang-gamibang is herbal medication prescribed for chronic facial palsy (where patients have passed the acute phase of the condition). In these patients, there has usually been more than 1 month since the onset of paralysis and there is often debility. 

![Fig. 4. Yanagihara score over the course of treatment. Compared with June 18th, 2020, the score increased by 2 points on July 16th, 2020.](image)

![Fig. 5. Photographs of improvement in ptosis over the treatment period (June 18th, 2020, June 25th, 2020, July 2nd, 2020, July 9th, 2020, July 16th, 2020).](image)

![Fig. 6. Photographs of keratography. Normal findings in dry eye.](image)
In addition, patients complain of a decrease in energy, so BIT-gamibang is used [15]. Kikukjihwangtang was prescribed for dry eye and other eye symptoms in the patient. The main ingredients of Kikukjihwangtang, Chrysanthemum indicum L., and Lycii Fructus have optic nerve protection and anti-inflammatory properties, and are therefore used for eye disease [16,17].

This patient was diagnosed with atypical MFS as a symptom of acute extraocular muscle palsy (which was 1 of the 3 main symptoms), and facial paralysis due to facial nerve palsy (a cranial nerve other than the ocular nerve). CKMT was administered during the 30 days of hospitalization. The diplopia questionnaire score decreased by 13 points. The occurrence of diplopia measured at a distance showed significant results (except for the right gaze). The range of diplopia decreased and the Yanagihara score increased by 2 points. Because this patient had bilateral facial paralysis, it was evaluated as an absolute evaluation instead of a relative evaluation comparing left and right.

A limitation of this study was the insufficient number of cases in this study (only 1 case), and the retrospective nature of this study. In addition to CKMT in the early part of treatment, steroids were also administered for 5 days. Studies evaluating the effectiveness of CKMT are lacking and it is difficult to know the effect of each treatment. Further prospective studies with CKMT and research on evaluation tools are needed.

However, there are few studies showing the effect of CKMT on MFS [18,19], and there is only 1 case of MFS associated with facial paralysis [20]. In addition, unlike previous studies, this study evaluated the degree of diplopia according to the gaze direction and the patient showed satisfactory improvement.

**Conflicts of Interest**

The authors have no conflicts of interest to declare.

**References**


---

**Appendix A. Diplopia Questionnaire.**

<table>
<thead>
<tr>
<th>Gaze position</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Always</strong></td>
<td></td>
</tr>
<tr>
<td>Straight ahead into the distance</td>
<td>6</td>
</tr>
<tr>
<td>Up</td>
<td>2</td>
</tr>
<tr>
<td>Down</td>
<td>4</td>
</tr>
<tr>
<td>Right</td>
<td>4</td>
</tr>
<tr>
<td>Left</td>
<td>4</td>
</tr>
<tr>
<td>Reading</td>
<td>4</td>
</tr>
<tr>
<td>Any position</td>
<td>1</td>
</tr>
<tr>
<td><strong>Sometimes</strong></td>
<td></td>
</tr>
<tr>
<td>Straight ahead into the distance</td>
<td>3</td>
</tr>
<tr>
<td>Up</td>
<td>1</td>
</tr>
<tr>
<td>Down</td>
<td>2</td>
</tr>
<tr>
<td>Right</td>
<td>2</td>
</tr>
<tr>
<td>Left</td>
<td>2</td>
</tr>
<tr>
<td>Reading</td>
<td>2</td>
</tr>
<tr>
<td>Any position</td>
<td>1</td>
</tr>
<tr>
<td><strong>Never</strong></td>
<td></td>
</tr>
<tr>
<td>Straight ahead into the distance</td>
<td>0</td>
</tr>
<tr>
<td>Up</td>
<td>0</td>
</tr>
<tr>
<td>Down</td>
<td>0</td>
</tr>
<tr>
<td>Right</td>
<td>0</td>
</tr>
<tr>
<td>Left</td>
<td>0</td>
</tr>
<tr>
<td>Reading</td>
<td>0</td>
</tr>
<tr>
<td>Any position</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>71</td>
</tr>
</tbody>
</table>